NovaBay and Eyenovia Begin Co-Promotion of Eyecare Products to Ophthalmic Surgery Centers
NovaBay and Eyenovia Begin Co-Promotion of Eyecare Products to Ophthalmic Surgery Centers
NovaBay Pharmaceuticals, Inc. (NYSE:NBY), a company developing and commercializing high-quality eyecare products, and Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, have commenced activities under a previously announced co-promotion agreement.
NovaBay Pharmaceuticals公司（紐交所股票代碼：NBY），一家開發和推廣高質量眼護產品的公司，與Eyenovia公司（納斯達克股票代碼：EYEN）合作推廣協議正式啓動。Eyenovia公司是一家商業階段眼科公司，擁有兩種FDA批准產品以及在兒童眼科前進性近視方面的後期資產。
Under the agreement, Eyenovia is leveraging its ten-person field salesforce to promote NovaBay's Avenova Antimicrobial Lid & Lash Solution to large ophthalmic surgery centers along with one of Eyenovia's other FDA-approved products, MydCombi for mydriasis. In parallel, NovaBay has initiated reconnaissance and market preparation activities ahead of Eyenovia's launch of Clobetasol Propionate Ophthalmic Suspension, 0.05%, an innovative, rapid, sustained and more convenient solution for the treatment of postoperative inflammation and pain. Clobetasol is expected to be commercially available in August 2024. NovaBay will conduct outreach through its telephone-based physician dispensed channel to supplement geographic areas not covered by Eyenovia.
根據協議，Eyenovia公司利用其10人現場銷售團隊向一些大型眼科手術中心以及Eyenovia的其他FDA批准產品MydCombi進行推廣，同時推廣NovaBay的Avenova抗菌眼簾護理溶液。與此同時，NovaBay公司正在進行偵察和市場準備活動，爲Eyenovia公司即將推出的Clobetasol Propionate Ophthalmic Suspension 0.05%做準備，這是一種更爲便捷的治療術後炎症和疼痛的創新、快速、持久的解決方案。預計Clobetasol將於2024年8月上市，NovaBay公司將通過其電話醫師分發渠道開展推廣，以補充Eyenovia公司未覆蓋地區。
譯文內容由第三人軟體翻譯。